Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Strong
Earnings
Very Weak
Growth
Earnings
Neutral
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Website
N/ATelephone
61.3.9824.5254
Address
Level 3, Suite 1 62 Lygon Street Carlton South, Victoria (VIC) 3053
Description
Arovella Therapeutics Ltd. engages in the development invariant Natural Killer (iNKT) cell platform for treatment of cancer. Its technologies include iNKT cell therapy, CAR19-iNKT + CF33-CD19, CLDN18.2-iNKT, and DKK1-CAR-iNKT. The company was founded on December 21, 1999 and is headquartered in Carlton South, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.07 - 0.21
Trade Value (12mth)
AU$54,228.00
1 week
-6.82%
1 month
13.89%
YTD
-51.76%
1 year
-34.4%
All time high
14.78
EPS 3 yr Growth
-38.80%
EBITDA Margin
%
Operating Cashflow
-$7m
Free Cash Flow Return
-92.10%
ROIC
-116.60%
Interest Coverage
-1,247.60
Quick Ratio
6.40
Shares on Issue (Fully Dilluted)
1054m
HALO Sector
Healthcare
Next Company Report Date
27-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.01
Date | Announcements |
---|---|
08 May 25 |
Results of Extraordinary General Meeting
×
Results of Extraordinary General Meeting |
05 May 25 |
ALA exclusive iNKT technology option with Baylor
×
ALA exclusive iNKT technology option with Baylor |
29 April 25 |
Investor webinar presentation
×
Investor webinar presentation |
24 April 25 |
Notification regarding unquoted securities - ALA
×
Notification regarding unquoted securities - ALA |
16 April 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
16 April 25 |
Quarterly Update Webinar
×
Quarterly Update Webinar |
10 April 25 |
Notice of Extraordinary General Meeting/Proxy Form
×
Notice of Extraordinary General Meeting/Proxy Form |
01 April 25 |
Cancel - Proposed issue of securities - ALA
×
Cancel - Proposed issue of securities - ALA |
01 April 25 |
Cancel - Proposed issue of securities - ALA
×
Cancel - Proposed issue of securities - ALA |
27 March 25 |
Notification of cessation of securities - ALA
×
Notification of cessation of securities - ALA |
26 March 25 |
Prospectus
×
Prospectus |
26 March 25 |
Proposed issue of securities - ALA
×
Proposed issue of securities - ALA |
26 March 25 |
Application for quotation of securities - ALA
×
Application for quotation of securities - ALA |
26 March 25 |
Quotation of Options
×
Quotation of Options |
07 March 25 |
S&P DJI Announces March 2025 Quarterly Rebalance
×
S&P DJI Announces March 2025 Quarterly Rebalance |
05 March 25 |
Application for quotation of securities - ALA
×
Application for quotation of securities - ALA |
05 March 25 |
Application for quotation of securities - ALA
×
Application for quotation of securities - ALA |
05 March 25 |
Top 20 Holders and Range of Units for Attaching Options
×
Top 20 Holders and Range of Units for Attaching Options |
03 March 25 |
Letter from Managing Director and CEO
×
Letter from Managing Director and CEO |
03 March 25 |
Research Agreement with University of North Carolina
×
Research Agreement with University of North Carolina |
27 February 25 |
Half Year Report and Appendix 4D
×
Half Year Report and Appendix 4D |
26 February 25 |
Arovella $15m Placement to fund Phase 1
×
Arovella $15m Placement to fund Phase 1 |
26 February 25 |
Prospectus
×
Prospectus |
26 February 25 |
Cancel - Proposed issue of securities - ALA
×
Cancel - Proposed issue of securities - ALA |
26 February 25 |
Proposed issue of securities - ALA
×
Proposed issue of securities - ALA |
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.